Balloon Dilation for Bladder Neck Contracture
Balloon dilation can treat selected nonobliterative posterior stenoses or provide access before incision. Bladder-neck stenosis after benign prostate surgery and VUAS after radical prostatectomy should be distinguished. EAU supports visually controlled dilation or DVIU for nonobliterative VUAS; resection or hot-knife incision is the recommended initial endoscopic approach for bladder-neck stenosis after benign outlet surgery. Do not attempt endoluminal treatment of complete posterior obliteration.[1]
See TUIBNC, TURBN, BNC, and the drug-coated balloon evidence page.
Technique and selection
Define the stenosis, prior treatment, radiation injury and baseline continence. Establish the true lumen under vision; use a guidewire and imaging as needed for safe positioning. Select the balloon and inflation parameters for the device and anatomy. Do not force access through an uncertain lumen or assume that dilation cannot injure the sphincter or create a false passage.[1]
Dilation can be repeated in selected nonobliterative recurrence, after discussion of durability and alternatives. Increasing obstruction, recurrent procedures, fistula or tissue necrosis should prompt reassessment rather than automatic further dilation.[1]
Conventional balloon evidence
| Study | Setting | Interpretation |
|---|---|---|
| Ramchandani 1994 | 27 balloon-treated patients within a 45-patient post-prostatectomy VUAS series | 16/27 (59%) successful. No new incontinence was reported in the balloon group; the small nonrandomized comparison does not establish the lowest incontinence risk among procedures.[2] |
| Nealon 2022 | 123 patients; 24 Fr balloon followed by bilateral Collins incisions | 101/123 (82.1%) patent after one procedure and 116/123 (94.3%) after a second; median follow-up 12 months. This is the outcome of the combined procedure, not the independent effect of balloon dilation.[3] |
These cohorts differ in selection, era, intervention and outcome definition. They cannot establish that one technique is intrinsically more effective or that a specific scar mechanism explains the difference in their percentages.
Drug-coated balloons in posterior stenosis
Posterior BNC/VUAS treatment with a paclitaxel-coated balloon is off-label. The FDA anterior-urethral indication and the ROBUST anterior-stricture trials must not be presented as posterior efficacy evidence. Current guideline-supported selection for anterior disease is narrower than all urethral stenoses; see the device pharmacology hub for labeling and paclitaxel precautions.[1]
Berg's retrospective comparative study included 65 DCB and 76 standard-treatment patients with posterior stenosis. Treatment was associated with better recurrence-free survival (log-rank p=0.013); adjusted HR was 0.40 (95% CI 0.19–0.87). This represents a 60% lower estimated hazard, not an absolute success rate or a proven 60% causal reduction in recurrence risk. Matching does not remove residual confounding, and long-term comparative durability remains uncertain.[4]
An international survey describes off-label adoption, but adoption frequency and an association with operator volume do not prove effectiveness or define a learning curve.[5]
For any DCB use, counsel using the current IFU: abstinence or condom use for 30 days, and avoidance of pregnancy with effective contraception for 6 months when a partner can become pregnant. These precautions apply even when the anatomical use itself is off-label. Drug and label details remain in the pharmacology hub.[6]
Complications and counseling
Discuss recurrence, bleeding, infection, extravasation and new or worsened incontinence. No available comparison establishes balloon dilation as having the lowest complication rate for every BNC/VUAS population. Radiation injury and the need for subsequent continence surgery require particular planning. Refractory stenosis warrants specialist reconstructive assessment; the choice depends on anatomy, bladder function and patient goals rather than a fixed sequence of increasingly novel devices.[1]
References
1. European Association of Urology. EAU Guidelines on Urethral Strictures. 2026. Disease management in males, sections 6.3.5–6.3.6. Guideline.
2. Ramchandani P, Banner MP, Berlin JW, Dannenbaum MS, Wein AJ. Vesicourethral anastomotic strictures after radical prostatectomy: efficacy of transurethral balloon dilation. Radiology. 1994;193(2):345-9. doi:10.1148/radiology.193.2.7972741.
3. Nealon SW, Bhanvadia RR, Badkhshan S, et al. Transurethral incisions for bladder neck contracture: comparable results without intralesional injections. J Clin Med. 2022;11(15):4355. doi:10.3390/jcm11154355.
4. Berg EK, Mehmedovic S, Askari D, et al. Efficacy of drug-coated balloon dilation vs endoscopic standard treatment in posterior urethral stenosis: a real-world comparative study. Urology. 2025. doi:10.1016/j.urology.2025.07.034.
5. Sugrue DD, O'Connor J, Białek Ł, et al. Practices in urethral stricture management with drug-coated balloon dilatation: an international survey. World J Urol. 2026;44(1):285. doi:10.1007/s00345-026-06343-y.
6. Urotronic. Optilume Urethral Drug Coated Balloon: FDA-approved instructions for use. FDA labeling.